Oncology clinical trials are more complex, and longer than those in other therapeutic areas. This fact demands unique and adaptive approaches to clinical research services. For future oncology trials to be successful, it is likely that a diagnostic allowing measurability of efficacy will be required. PSNResearch believes that identifying biomarkers for the purpose of determining clinical endpoints, as early in the clinical process as possible, will be key to good Phase II and Phase III protocol design.
Furthermore, patient enrollment in oncology trials is increasingly an impediment to clinical trial success and confirmatory outcomes. PSNRsearch has built its success on a very good enrollment track record and a commitment to excellence in clinical operations. We know the intricacies of oncology clinical research, and we know the science of blood-borne disease.
Our oncology experience includes Phase I-IV trials encompassing nearly 7500 patients at 2600 sites, including but not limited to the following indications:
Data Protection: PSNResearch collects, stores and processes data exclusively for the purpose of business operation and according to PSNResearch’s Data Protection Policy. Any personal information submitted to PSNResearch on the contact form is used and stored as an e-mail. PSNResearch will only store your e-mail data for as long as is necessary for the purpose of business operation. When this purpose is no longer relevant the data sets will be deleted as part of PSNResearch’s routine operations.
